SHENZHEN, CHINA--(Marketwire - 07/29/10) - Hard to Treat Diseases, Inc. (Pinksheets:HTDS - News)(http://www.htdsmedical.com) announces the company’s intention to sell current subsidiary Slavica Biochem to a US-based publicly traded biomedical company.
HTDS is pleased with the performance of Slavica, a Belgrade-based medical research centre that is currently evaluating various medications and clinical trials geared toward identifying effective treatments for neurological disorders such as Multiple Sclerosis. This divestiture is nonetheless sought after because the interested company is making a substantial offer for the HTDS subsidiary, which will fit will in the prospective purchaser’s own portfolio.
The intended buyer of Slavica Biochem finds novel uses for currently marketed or near market drugs or therapeutic treatments. This company operates in a variety of market segments through the refinement and improvement of key parts of the value chain, and by enhancing company portfolios through strategic partnerships and in-licensing pharmaceuticals. Slavica technologies and methodology fit perfectly within the buyer’s business realm, which is why the offer to purchase Slavica from HTDS is so lucrative.
The expected sale of Slavica Biochem, plus the soon to be announced divestiture of HTDS subsidiary Collagenna Skin Care Products, will allow HTDS to focus on its core business, China-based vaccine distributor Shenzhen Mellow Hope.
About Mina Mar Group:
Mina Mar Group pioneered the “Go Public Free” program, the first firm to challenge the short sellers, stock bashers and repeal of the “Communication Decency Act”. Visit www.minamargroup.com/ice to learn more.
Mina Mar Marketing Group, MMMG (www.minamargroup.net/) offers publicly traded companies full array of services such as Investor Relations and maintenance investor awareness.
To be included in company’s email database for press releases, “Friday Tips”, industry updates, and company activity that may or may not be news released, please subscribe for opt-in mailer at http://www.minamargroup.com/updates.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases “can be,” “expects,” “may affect,” “believed,” “estimate,” “project” and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases, Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases, Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
